Efficacy of azilsartan medoxomil in patients with hypertension and stable coronary artery disease in combination with type 2 diabetes

IF 0.3 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS

Rational Pharmacotherapy in Cardiology Pub Date : 2023-11-07 DOI:10.20996/1819-6446-2023-2948

A. Kochergina, O. Barbarash

{"title":"Efficacy of azilsartan medoxomil in patients with hypertension and stable coronary artery disease in combination with type 2 diabetes","authors":"A. Kochergina, O. Barbarash","doi":"10.20996/1819-6446-2023-2948","DOIUrl":null,"url":null,"abstract":"Aim. To study the effect of azilsartan medoxomil (AZL-M) on the 24-hour blood pressure (BP) profile in patients with hypertension (HTN), type 2 diabetes (T2D) and stable coronary artery disease (CAD).Material and methods. A total of 183 patients with CAD in combination with HTN and T2D took part in the study (100 men (54,64%), 83 women (45,36%)). All patients were previously prescribed a statin, antiplatelet therapy, a beta-blocker, and an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB). At baseline, the proportion of people taking ARBs and ACEIs was 30% and 70%, respectively. All study participants were discontinued from a previously prescribed ARBs or ACE inhibitors and were prescribed 6-month AZL-M (Edarbi®) therapy. During this period, according to the study plan, patients visited the medical center to assess the effectiveness and safety of therapy and blood pressure changes.Results. The mean age of the patients was 65,0 years (60-69 years), while the mean body mass index (BMI) — 31,24 kg/m2. The mean age of female participants was higher than the mean age of males: 66,35±6,59 vs 62,72±8,82 years (p=0,002). The mean BMI in women was higher and was 33.08 kg/m2, while in men it was 30,74 kg/m2 (p=0,001). Six-month AZL-M therapy decreased 24-hour BP values. Thus, the time index of systolic blood pressure (SBP) hypertension in the daytime decreased from 63% to 12%, while at night from 70% to 10%, and the time index of diastolic blood pressure (DBP) hypertension in the daytime from 18% to 10%, and at night from 44% to 8%. The main result is confirmation of AZL-M effectiveness in relation to BP control, as well as good drug tolerability. At the visit after 1-month AZL-M therapy, target BP values were recorded in 45,4% of participants, and after six months — the proportion of people with normal 24-hour BP values was 69,9%.Conclusion. Edarbi® therapy in patients with HTN in combination with T2D and stable CAD leads to 24-hour BP normalization. At the same time, the drug has a good safety profile, since the reported adverse events were not related to the drug.","PeriodicalId":20812,"journal":{"name":"Rational Pharmacotherapy in Cardiology","volume":"126 1","pages":""},"PeriodicalIF":0.3000,"publicationDate":"2023-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rational Pharmacotherapy in Cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20996/1819-6446-2023-2948","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Aim. To study the effect of azilsartan medoxomil (AZL-M) on the 24-hour blood pressure (BP) profile in patients with hypertension (HTN), type 2 diabetes (T2D) and stable coronary artery disease (CAD).Material and methods. A total of 183 patients with CAD in combination with HTN and T2D took part in the study (100 men (54,64%), 83 women (45,36%)). All patients were previously prescribed a statin, antiplatelet therapy, a beta-blocker, and an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB). At baseline, the proportion of people taking ARBs and ACEIs was 30% and 70%, respectively. All study participants were discontinued from a previously prescribed ARBs or ACE inhibitors and were prescribed 6-month AZL-M (Edarbi®) therapy. During this period, according to the study plan, patients visited the medical center to assess the effectiveness and safety of therapy and blood pressure changes.Results. The mean age of the patients was 65,0 years (60-69 years), while the mean body mass index (BMI) — 31,24 kg/m2. The mean age of female participants was higher than the mean age of males: 66,35±6,59 vs 62,72±8,82 years (p=0,002). The mean BMI in women was higher and was 33.08 kg/m2, while in men it was 30,74 kg/m2 (p=0,001). Six-month AZL-M therapy decreased 24-hour BP values. Thus, the time index of systolic blood pressure (SBP) hypertension in the daytime decreased from 63% to 12%, while at night from 70% to 10%, and the time index of diastolic blood pressure (DBP) hypertension in the daytime from 18% to 10%, and at night from 44% to 8%. The main result is confirmation of AZL-M effectiveness in relation to BP control, as well as good drug tolerability. At the visit after 1-month AZL-M therapy, target BP values were recorded in 45,4% of participants, and after six months — the proportion of people with normal 24-hour BP values was 69,9%.Conclusion. Edarbi® therapy in patients with HTN in combination with T2D and stable CAD leads to 24-hour BP normalization. At the same time, the drug has a good safety profile, since the reported adverse events were not related to the drug.

查看原文本刊更多论文

阿齐沙坦酯联合 2 型糖尿病对高血压和稳定型冠心病患者的疗效

研究目的研究阿齐沙坦酯（AZL-M）对高血压（HTN）、2型糖尿病（T2D）和稳定型冠状动脉疾病（CAD）患者24小时血压（BP）曲线的影响。共有 183 名合并高血压和 2 型糖尿病的冠心病患者参加了研究（其中 100 名男性（54.64%），83 名女性（45.36%））。所有患者之前都服用过他汀类药物、抗血小板疗法、β-受体阻滞剂、血管紧张素转换酶抑制剂（ACEI）或血管紧张素受体阻滞剂（ARB）。基线时，服用 ARB 和 ACEI 的比例分别为 30% 和 70%。所有研究参与者都停用了之前开具的 ARB 或 ACE 抑制剂，并接受了为期 6 个月的 AZL-M (Edarbi®) 治疗。在此期间，根据研究计划，患者到医疗中心评估治疗的有效性和安全性以及血压变化。患者的平均年龄为 65.0 岁（60-69 岁），平均体重指数（BMI）为 31.24 kg/m2。女性参与者的平均年龄高于男性：66,35±6,59 岁 vs 62,72±8,82 岁（P=0,002）。女性的平均体重指数较高，为 33.08 kg/m2，而男性为 30.74 kg/m2（P=0.001）。为期六个月的 AZL-M 治疗降低了 24 小时血压值。因此，日间收缩压（SBP）高血压时间指数从 63% 降至 12%，夜间从 70% 降至 10%；日间舒张压（DBP）高血压时间指数从 18% 降至 10%，夜间从 44% 降至 8%。主要结果证实了 AZL-M 在控制血压方面的有效性，以及良好的药物耐受性。在接受 AZL-M 治疗 1 个月后的回访中，45.4% 的参与者记录到了目标血压值，而在 6 个月后，24 小时血压值正常者的比例为 69.9%。Edarbi®治疗合并有T2D和稳定型CAD的高血压患者可使24小时血压恢复正常。同时，该药物具有良好的安全性，因为报告的不良事件与该药物无关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Rational Pharmacotherapy in Cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

1.00

自引率

50.00%

发文量

审稿时长

6 weeks

期刊介绍： The primary goals of the Journal are consolidation of information on scientific and practical achievements in pharmacotherapy and prevention of cardiovascular diseases and continuing education of cardiologists and internists. The scientific concept of the edition suggests the publication of information on current achievements in cardiology, the results of national and international clinical trials. The Journal publishes original articles on the results of clinical trials designed to study the effectiveness and safety of drugs, analysis of clinical practice and its compliance with national and international recommendations, expert s’ opinions on a wide range of cardiology issues, associated conditions and clinical pharmacology. There is a heading “Preventive cardiology and public health” in the Journal to stimulate research interest in this highly demanded area. Memories of the outstanding people in medicine including cardiology, which are of great interest to historians of medicine, are published in "Our Mentors” heading.